Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies.
alveolar hypoxia
cardiac dysfunction
chronic thromboembolic pulmonary hypertension (CTEPH)
neurostimulation and electroacupuncture
pulmonary arterial hypertension (PAH)
pulmonary hypertension (PH)
vascular remodeling
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
04 Oct 2024
04 Oct 2024
Historique:
received:
31
08
2024
revised:
23
09
2024
accepted:
01
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
epublish
Résumé
Pulmonary hypertension (PH) is a severe and chronic disease characterized by increased pulmonary vascular resistance and remodeling, often precipitating right-sided heart dysfunction and death. Although the condition is progressive and incurable, current therapies for the disease focus on multiple different drugs and general supportive therapies to manage symptoms and prolong survival, ranging from medications more specific to pulmonary arterial hypertension (PAH) to exercise training. Moreover, there are multiple studies exploring novel experimental drugs and therapies including unique neurostimulation, to help better manage the disease. Here, we provide a narrative review focusing on current PH treatments that target multiple underlying biochemical mechanisms, including imbalances in vasoconstrictor-vasodilator and autonomic nervous system function, inflammation, and bone morphogenic protein (BMP) signaling. We also focus on the potential of novel therapies for managing PH, focusing on multiple types of neurostimulation including acupuncture. Lastly, we also touch upon the disease's different subgroups, clinical presentations and prognosis, diagnostics, demographics, and cost.
Identifiants
pubmed: 39459565
pii: life14101265
doi: 10.3390/life14101265
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : NCCIH NIH HHS
ID : RO1 AT011306
Pays : United States